Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: A randomized multicenter trial

Internal Medicine

Volumn 52, Issue 7, 2013, Pages 735-744

  Nishijima, Takeshi ^a,b   Takano, Misao ^a   Ishisaka, Michiyo ^a   Komatsu, Hirokazu ^c   Gatanaga, Hiroyuki ^a,b   Kikuchi, Yoshimi ^a   Endo, Tomoyuki ^d   Horiba, Masahide ^e   Kaneda, Satoru ^f   Uchiumi, Hideki ^g   Koibuchi, Tomohiko ^h   Naito, Toshio ⁱ   Yoshida, Masaki ^j   Tachikawa, Natsuo ^k   Ueda, Mikio ^l   Yokomaku, Yoshiyuki ^m   Fujii, Teruhisa ⁿ   Higasa, Satoshi ^o   Takada, Kiyonori ^p   Yamamoto, Masahiro ^q   Matsushita, Shuzo ^b   Tateyama, Masao ^r   Tanabe, Yoshinari ^s   Mitsuya, Hiroaki ^b,t   Oka, Shinichi ^a,b   more..

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^e Higashisaitama National Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION CHIBA MEDICAL CENTER   (Japan)

^g GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^l ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁿ HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^o HYOGO COLLEGE OF MEDICINE   (Japan)

^p EHIME UNIVERSITY HOSPITAL   (Japan)

^q NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^r UNIVERSITY OF THE RYUKYUS   (Japan)

^s NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^t NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Abacavir lamivudine; HIV 1 infection; HLA B*5701 negative; Ritonavir boosted atazanavir; Tenofovir emtricitabine; Treatment na ve Asian patients

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BETA 2 MICROGLOBULIN; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FENOFIBRATE; HLA B ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRAIN INFARCTION; CALCIUM BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERSENSITIVITY; JAUNDICE; KIDNEY DISEASE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PILOT PROJECTS; PYRIDINES; RITONAVIR; TREATMENT OUTCOME;

EID: 84875896824     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9155     Document Type: Article

References (34)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [http: / / www. aidsinfo. nih. gov / contentfiles / lvguidelines / adultandadolescentgl.pdf].
2. European AIDS Clinical Society Guidelines version 6 [http://www. europeanaidsclinicalsociety. org / images / stories / EACS-Pdf / EACSGuidelines-v6.0-English.pdf].
3. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361: 2230-2240, 2009.
4. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23: 1547-1556, 2009.
5. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23: 1603-1614, 2001.
6. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358: 568-579, 2008.
7. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 9: 207-214, 2008.
8. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIVinfected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426, 2008.
9. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA metaanalysis. J Acquir Immune Defic Syndr 61: 441-447, 2012.
10. Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269-273, 2004.
11. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40: 1331-1333, 2002.
12. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analoguecontaining regimen in antiretroviral-naive patients. AIDS 22: 2155-2163, 2008.
13. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505, 2010.
14. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203: 1791-1801, 2011.
15. Guidelines for antiretroviral therapy. Japanese Ministry of Health and Welfare, in Japanese. [http://www.haart-support.jp/pdf/ guideline2012.pdf].
16. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 204: 1191-1201, 2011.
17. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 55: 49-57, 2010.
18. Nishijima T, Gatanaga H, Komatsu H, et al. Renal function de clines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One 7: e29977, 2012.
19. Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res 8: 504-509, 2010.
20. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21: 1273-1281, 2007.
21. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One 6: e22661, 2011.
22. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340: c869, 2010.
23. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents October 10, 2006. [http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL000629.pdf].
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
25. Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drugresistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 88: 72-79, 2010.
26. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48: e108-e116, 2009.
27. DIVISION OF AIDS TABLE FOR GRADING THE SEVERITY OF ADULT AND PEDIATRIC ADVERSE EVENTS VERSION 1.0, DECEMBER, 2004; CLARIFICATION AUGUST 2009. [http://www.mtnstopshiv.org/sites/default/files/attachments/Table_ for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf].
28. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.
29. Kudo K, Konta T, Mashima Y, et al. The association between renal tubular damage and rapid renal deterioration in the Japanese population: the Takahata study. Clin Exp Nephrol 15: 235-241, 2011.
30. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Kidney tubular damage in the absence of glomerular defects in HIVinfected patients on highly active antiretroviral therapy. Nephrol Dial Transplant 26: 3224-3229, 2011.
31. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary G2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 22: 744-748, 2006.
32. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 43: 103-105, 2006.
33. Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 60: 599-604, 2007.
34. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 91: 734-738, 2012.